- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 2,840
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic or Unresectable Cutaneous Melanoma
- Interventions
- MEK162, Dacarbazine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 77
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Altamonte Springs, Florida + 46 more
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms, Cholangiocarcinoma, Breast Cancer
- Interventions
- Paclitaxel, Nilotinib, ECG, CT Scan CAP, Laparoscopy, Peritoneal biopsies + ascites washings
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Melanoma, Brain Metastases
- Interventions
- Ipilimumab, Stereotactic Radiosurgery
- Drug · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
- Interventions
- Not listed
- Lead sponsor
- SpeciCare
- Industry
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Georgia
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 22 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
- Interventions
- Behavioral Dietary Intervention, Text Message-Based Navigation Intervention, Internet-Based Intervention, Dietary Counseling and Surveillance, Stereotactic Radiosurgery, Biospecimen Collection, Magnetic Resonance Imaging, Neurocognitive Assessment, Questionnaire Administration, Interview
- Behavioral · Other · Radiation + 1 more
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Malignant Melanoma
- Interventions
- Vemurafenib, Dacarbazine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Cancer
- Interventions
- GSK2118436, Dacarbazine (DTIC)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 8 more
- Conditions
- Cancer
- Interventions
- capecitabine, cisplatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, capecitabine, paclitaxel
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer, GastroEsophageal Cancer, Renal Cell Carcinoma, MSI-H
- Interventions
- EDP1503, Pembrolizumab
- Biological
- Lead sponsor
- Evelo Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Temozolomide, Cisplatin, Interferon Alfa-2b, Interleukin-2
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Melanoma
- Interventions
- Placebo for antibiotic, Vancomycin pretreatment, Nivolumab, Matching Placebo for SER-401, SER-401
- Drug
- Lead sponsor
- Parker Institute for Cancer Immunotherapy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, Carboplatin, ABI-007
- Biological · Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 6
- States / cities
- Downers Grove, Illinois • Geneva, Illinois • Maywood, Illinois + 3 more
- Conditions
- First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
- Interventions
- Zoledronic acid, Standard Therapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 33
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 30 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer, Stage IV Inflammatory Breast Carcinoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
- Interventions
- Arm 1
- Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Interventions
- Peptide vaccine, GM-CSF, PF3512676
- Biological
- Lead sponsor
- Ahmad Tarhini
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Solid Tumors, Stage 4 Cancer
- Interventions
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Device
- Lead sponsor
- New Phase Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
- Interventions
- SKB264
- Drug
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
- Conditions
- Head and Neck Neoplasms
- Interventions
- Gefitinib
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Miami, Florida • Chicago, Illinois